EKF Diagnostics Holding plc Announces Preferred Partner Arrangement with Mount Sinai
Opportunity to support digital health platform for Inflammatory Bowel Disease September 10, 2019 — EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it has entered into a non-exclusive Preferred Partner Arrangement with Mount Sinai Innovation Partners (MSIP). MSIP is …
Moving Science into the Clinic
How Mount Sinai Drives Real-World Applications of Research Discoveries By Douglas McCormick From the fall issue of Mount Sinai Science & Medicine magazine The long-anticipated combination of artificial intelligence and molecular biology is now producing personalized, precision treatments for patients at Mount …
Life Science Academic Partnerships Part 1: an Ideal Marriage to Fuel Organic Growth
By Mark Ralph, Executive Director & Global Head, Contracts & Alliance Management, Boehringer Ingelheim Pharmaceuticals, Inc. In today’s innovation environment, external collaboration is one of the most powerful methods to discover and develop new treatments and research tools, particularly between industry and …
FDA Grants Breakthrough Device Designation to KidneyIntelX™
Provides Priority Regulatory Review of AI-Enabled Diagnostic for Fast-Progressing Kidney Disease NEW YORK, May 2, 2019 /PRNewswire/ – Renalytix AI plc (RENX.L), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that it has been granted Breakthrough Device designation by the U.S. Food …
Mount Sinai Partners with Paradigm Biopharmaceuticals Ltd. and ReqMed Company, Ltd. to Repurpose Drug to Battle Rare MPS Diseases
New York, NY (January 15, 2019) – The Icahn School of Medicine at Mount Sinai has entered into two exclusive licenses to develop the drug pentosan polysulfate sodium for the treatment of mucopolysaccharidosis (MPS), with Australia-based company Paradigm Biopharmaceuticals Ltd. (ASX: PAR) …
Sanofi, Sema4, Mount Sinai Collaborate on Largest Asthma Study of Its Kind
New York, NY (December 04, 2018) — Sema4, a patient-centered predictive health company, and the Mount Sinai Health System today announced the launch of a five-year collaborative study with Sanofi designed to provide new insights into the biological mechanisms and other factors …
RenalytixAI Raises $29 Million to Commercialize AI-Enabled Clinical Diagnostic Solutions for Kidney Disease
Mount Sinai Health System announced today that RenalytixAI PLC, a Mount Sinai exclusive licensee and development collaborator, had completed a public listing that valued the company at $85 million on the London Stock Exchange’s Alternative Investment Market. The public listing raised $29 …
Mount Sinai and AllerGenis, LLC Announce Partnership to Bring Novel, Precision Diagnostics to Food Allergy Patients
New Diagnostic Technology Will Provide Information to Both Patients and Clinicians More than 30 million people in the United States and Europe have food allergies, according to the National Institute of Allergy and Infectious Diseases, National Institutes of Health. AllerGenis’ food allergy …
MSIP Recognizes Innovators at 2018 SINAInnovations Awards Ceremony
Mount Sinai Innovation Partners (MSIP) presented the Inventor of the Year award to Anne Schaefer, MD, PhD, and the Deal of the Year award to Julio A. Aguirre-Ghiso, PhD, at the 2018 SinaInnovations awards ceremony. The awards recognize exceptional Mount Sinai innovators …